-+ 0.00%
-+ 0.00%
-+ 0.00%

Cornerstone Pharmaceuticals announced that shares issued by the company and listed on the Hong Kong Stock Exchange Limited have been included in the Hong Kong Stock Exchange List, effective from September 7, 2026. The company's core asset CS2009 global phase I/II clinical trials are progressing, and it is expected that the first batch of global phase III registered clinical trials will begin before the end of 2026.

Zhitongcaijing·09/07/2026 00:17:08
Listen to the news
Cornerstone Pharmaceuticals announced that shares issued by the company and listed on the Hong Kong Stock Exchange Limited have been included in the Hong Kong Stock Exchange List, effective from September 7, 2026. The company's core asset CS2009 global phase I/II clinical trials are progressing, and it is expected that the first batch of global phase III registered clinical trials will begin before the end of 2026.